Abstract:Adaptation of the lipid metabolism participates in cancer pathogenesis, facilitating energy storage and influencing cell fate and control of molecular signalling. The tumour suppressor protein p53 is a molecular hub of cell metabolism, supporting antioxidant capabilities and counteracting oncogene-induced metabolic switch. Despite extensive work has described the p53-dependent metabolic pathways, a global profiling of p53 lipidome is still missing. By high-throughput untargeted lipidomic analysis of pancreatic ductal adenocarcinoma (PDAC) cells, we profile the p53-dependent lipidome, revealing intracellular and secreted lysophospholipids as one of the most affected class. Lysophospholipids are hydrolysed forms of phospholipids that results from phospholipase activity, which can function as signalling molecules, exerting non-cell-autonomous effects and instructing cancer microenvironment and immunity. Here, we reveal that p53 depletion reduces abundance of intracellular lysophosphatidyl-choline, -ethanolamine and -serine and their secretion in the extracellular environment. By integrating this with genomic and transcriptomic studies from in vitro models and human PDAC patients, we identified potential clinically relevant candidate p53-dependent phospholipases. In particular PLD3, PLCB4 and PLCD4 expression is regulated by p53 and chromatin immunoprecipitation followed by deep sequencing (ChIP-seq) indicates a direct transcriptional control on their chromatin accessible genomic loci. Consistently, PLD3, PLCB4 and PLCD4 expression correlates with p53 mutational status in PDAC patients, and these genes display prognostic significance. Overall, our data provide insights into lipidome rewiring driven by p53 loss and identify alterations of lysophospholipids as a potential molecular mechanism for p53-mediated non-cell-autonomous molecular signalling that instructs cancer microenvironment and immunity during PDAC pathogenesis.

p53 suppresses lipid droplet–fueled tumorigenesis through phosphatidylcholine

Cholesteryl Ester Accumulation Induced by PTEN Loss and PI3K/AKT Activation Underlies Human Prostate Cancer Aggressiveness

Cholesterol esterification and p53-mediated tumor suppression

p53 regulates lipid metabolism in cancer

P53 Deficiency Affects Cholesterol Esterification to Exacerbate Hepatocarcinogenesis.

p53 transcriptionally regulates SQLE to repress cholesterol synthesis and tumor growth

p53-driven lipidome influences non-cell-autonomous lysophospholipids in pancreatic cancer

Silencing of Functional P53 Attenuates NAFLD by Promoting HMGB1-related Autophagy Induction

p53 promotes peroxisomal fatty acid beta-oxidation to repress purine biosynthesis and mediate tumor suppression

p53 promotes peroxisomal fatty acid β-oxidation to repress purine biosynthesis and mediate tumor suppression

p53 promotes peroxisomal fatty acid -oxidation to repress purine biosynthesis and mediate tumor suppression

p53 as a double-edged sword in the progression of non-alcoholic fatty liver disease

P53-Mediated Regulation of Bile Acid Disposition Attenuates Cholic Acid-Induced Cholestasis in Mice

DNA methylation modifier LSH inhibits p53 ubiquitination and transactivates p53 to promote lipid metabolism

Suppression of P53 Potentiates Chemosensitivity in Nutrient-Deprived Cholangiocarcinoma Cells Via Inhibition of Autophagy

Choline-induced SLC5A7 impairs colorectal cancer growth by stabilizing p53 protein

Inhibition of p53 increases chemosensitivity to 5-FU in nutrient-deprived hepatocarcinoma cells by suppressing autophagy.

P53/lactate Dehydrogenase A Axis Negatively Regulates Aerobic Glycolysis and Tumor Progression in Breast Cancer Expressing Wild-Type P53.

Elevated choline drives KLF5-dominated transcriptional reprogramming to facilitate liver cancer progression

Ribosomal Protein-Mdm2-P53 Pathway Coordinates Nutrient Stress with Lipid Metabolism by Regulating Mcd and Promoting Fatty Acid Oxidation

P53 Coordinates Glucose and Choline Metabolism During the Mesendoderm Differentiation of Human Embryonic Stem Cells.